Cargando…
Outcomes over the first two years of treatment with mepolizumab in severe asthma
This study found that 30% of patients stopped mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab. https://bit.ly/3ChWN63
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696189/ https://www.ncbi.nlm.nih.gov/pubmed/34711539 http://dx.doi.org/10.1183/13993003.01313-2021 |